ADCT (ADC Therapeutics) Total Inventories : $17.45 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Total Inventories?

ADC Therapeutics's total inventories for the quarter that ended in Mar. 2025 was $17.45 Mil. ADC Therapeutics's average total inventories from the quarter that ended in Dec. 2024 to the quarter that ended in Mar. 2025 was $17.92 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. ADC Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2025 was $-2.86.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. ADC Therapeutics's Days Inventory for the three months ended in Mar. 2025 was 793.27.

Inventory Turnover measures how fast the company turns over its inventory within a year. ADC Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2025 was 0.12.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. ADC Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2025 was 0.78.

ADC Therapeutics Total Inventories Historical Data

The historical data trend for ADC Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Total Inventories Chart

ADC Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Inventories

Get a 7-Day Free Trial

11.12

12.07

16.18

18.39

ADC Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Inventories	Get a 7-Day Free Trial															16.00	15.19	16.07	18.39	17.45

ADC Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

ADC Therapeutics (NYSE:ADCT) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

ADC Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2025 is

	Net-Net Working Capital Per Share (Q: Mar. 2025 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(194.701	+	0.75 * 31.762	+	0.5 * 17.447	-	510.762
-	0	-	0)	/	99.178
=	-2.86

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ADC Therapeutics's Days Inventory for the three months ended in Mar. 2025 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2025 )	/	Cost of Goods Sold (Q: Mar. 2025 )	*	Days in Period
	=	17.917	/	2.061	*	365 / 4
	=	793.27

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

ADC Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2025 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2025 )	/	Average Total Inventories (Q: Mar. 2025 )
	=	2.061	/	17.917
	=	0.12

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ADC Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2025 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	17.917	/	23.033
	=	0.78

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

ADC Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

ADC Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066

Website

https://www.adctherapeutics.com

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).